Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aarti Drugs Limited (AARTIDRUGS.NS)
Mumbai, IN
Operating both within India and globally, Aarti Drugs Limited, along with its affiliated companies, specializes in the pharmaceutical sector. Its product portfolio encompasses a wide range of active pharmaceutical ingredients (APIs) across numerous therapeutic areas, such as anti-inflammatory, cardiovascular protection, antidiarrheal, antifungal, anti-arthritis/osteoporosis, antibiotic, antidiabetic, Alzheimer's disease management, sedative, vitamin, and alcoholism treatment. Additionally, it supplies pharmaceutical intermediate compounds, including tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, the company manufactures and distributes various specialty chemicals. These include a comprehensive list of compounds such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl hydrazide, benzene sulphonic acid and its sodium salt, benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. Aarti Drugs also maintains a robust development pipeline, featuring products such as Acamprosate, intended for treating alcoholism; Dabigatran, an anticoagulant; Sevelamer, for managing hyperphosphatemia; Colesevelam, aimed at lowering cholesterol; Dronedarone and Olmesartan, both for cardiovascular disease treatment; Valsartan, which acts as a cardioprotectant; and Sitagliptin, an antidiabetic agent. Moreover, the firm provides contract manufacturing solutions. Established in 1984, the company's main operations are based in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.37% | +6.68% | +6.19% | +5.39% | -9.51% | -5.41% | -16.66% | -12.72% | -47.30% | +236.24% | +3,546.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.5% ★ Q1'26: +6.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+16.4% Q1'26: -12.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.0% Q1'26: +8.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.4% Q1'26: +10.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.6% ★ Q1'26: +11.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.86× Q1'26: 1.50× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2010 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.79B
est: 12.52B (-61.8%)
|
8.25B
est: 8.61B (-4.2%)
|
9.70B
est: 9.58B (+1.2%)
|
10.94B
est: 11.22B (-2.4%)
|
11.35B
est: 11.21B (+1.2%)
|
11.95B
est: 12.50B (-4.4%)
|
12.44B
est: 12.00B (+3.6%)
|
15.61B
est: 14.52B (+7.5%)
|
18.06B
est: 18.34B (-1.5%)
|
21.55B
est: 21.96B (-1.9%)
|
24.89B
est: 24.55B (+1.4%)
|
27.16B
est: 26.57B (+2.2%)
|
25.29B
est: 26.10B (-3.1%)
|
23.87B
est: 23.00B (+3.8%)
|
26.10B
26.10B – 26.10B
+13.5% YoY
|
29.50B
29.50B – 29.50B
+13.0% YoY
|
33.20B
33.20B – 33.20B
+12.5% YoY
|
| EBITDA |
857.71M
est: 1.77B (-51.5%)
|
1.20B
est: 1.19B (+0.8%)
|
1.46B
est: 1.33B (+10.2%)
|
1.70B
est: 1.00B (+69.2%)
|
1.80B
est: 1.04B (+72.8%)
|
1.94B
est: 1.77B (+10.1%)
|
2.03B
est: 1.15B (+76.4%)
|
2.17B
est: 1.57B (+38.1%)
|
2.71B
est: 1.72B (+58.2%)
|
4.42B
est: 2.36B (+87.5%)
|
3.44B
est: 2.72B (+26.4%)
|
3.12B
est: 3.37B (-7.5%)
|
3.25B
est: 4.03B (-19.5%)
|
2.87B
est: 2.86B (+0.3%)
|
3.25B
3.25B – 3.25B
+13.5% YoY
|
3.67B
3.67B – 3.67B
+13.0% YoY
|
4.13B
4.13B – 4.13B
+12.5% YoY
|
| EBIT |
660.61M
est: 1.51B (-56.1%)
|
943.50M
est: 1.02B (-7.1%)
|
1.18B
est: 1.13B (+4.7%)
|
1.39B
est: 1.45B (-4.1%)
|
1.39B
est: 1.53B (-9.0%)
|
1.52B
est: 1.50B (+1.4%)
|
1.59B
est: 1.50B (+6.4%)
|
1.71B
est: 1.93B (-11.4%)
|
2.19B
est: 2.13B (+3.0%)
|
3.92B
est: 2.51B (+56.2%)
|
2.94B
est: 2.90B (+1.4%)
|
2.61B
est: 3.59B (-27.2%)
|
2.73B
est: 4.30B (-36.4%)
|
2.31B
est: 2.36B (-2.1%)
|
2.68B
2.68B – 2.68B
+13.5% YoY
|
3.03B
3.03B – 3.03B
+13.0% YoY
|
3.41B
3.41B – 3.41B
+12.5% YoY
|
| Net Income |
282.30M
est: 504.75M (-44.1%)
|
452.38M
est: 1.77B (-74.4%)
|
617.12M
est: 2.10B (-70.5%)
|
772.54M
est: 741.78M (+4.1%)
|
687.25M
est: 851.51M (-19.3%)
|
805.63M
est: 762.90M (+5.6%)
|
823.07M
est: 796.58M (+3.3%)
|
897.52M
est: 982.18M (-8.6%)
|
1.41B
est: 1.13B (+24.8%)
|
2.80B
est: 1.64B (+71.3%)
|
2.05B
est: 1.89B (+8.4%)
|
1.66B
est: 2.34B (-29.0%)
|
1.71B
est: 2.80B (-38.9%)
|
1.68B
est: 1.41B (+18.9%)
|
1.83B
1.83B – 1.83B
+29.0% YoY
|
2.25B
2.25B – 2.25B
+23.5% YoY
|
2.66B
2.66B – 2.66B
+18.2% YoY
|
| SGA |
223.82M
est: 486.61M (-54.0%)
|
238.77M
est: 328.14M (-27.2%)
|
292.83M
est: 365.18M (-19.8%)
|
288.60M
est: 805.50M (-64.2%)
|
278.39M
est: 781.28M (-64.4%)
|
307.69M
est: 485.75M (-36.7%)
|
346.19M
est: 897.29M (-61.4%)
|
386.40M
est: 1.22B (-68.4%)
|
626.16M
est: 1.38B (-54.7%)
|
815.37M
est: 1.67B (-51.1%)
|
840.53M
est: 1.93B (-56.4%)
|
933.07M
est: 2.39B (-60.9%)
|
1.05B
est: 2.86B (-63.3%)
|
1.12B
est: 1.63B (-31.3%)
|
1.85B
1.85B – 1.85B
+13.5% YoY
|
2.09B
2.09B – 2.09B
+13.0% YoY
|
2.35B
2.35B – 2.35B
+12.5% YoY
|
| EPS |
2.99
est: 5.51 (-45.7%)
|
4.67
est: 19.37 (-75.9%)
|
6.37
est: 22.98 (-72.3%)
|
7.98
est: 8.61 (-7.3%)
|
7.10
est: 7.18 (-1.0%)
|
8.37
est: 8.33 (+0.5%)
|
8.73
est: 8.48 (+3.0%)
|
9.51
est: 8.95 (+6.3%)
|
15.17
est: 12.34 (+23.0%)
|
30.09
est: 31.95 (-5.8%)
|
22.14
est: 23.30 (-5.0%)
|
17.96
est: 17.63 (+1.9%)
|
18.56
est: 18.70 (-0.7%)
|
18.35
est: 15.50 (+18.4%)
|
20.00
20.00 – 20.00
+29.0% YoY
|
24.70
24.70 – 24.70
+23.5% YoY
|
29.20
29.20 – 29.20
+18.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Prakash Moreshwar Patil | Chairman, MD & Chief Executive Officer | 29M | male |
| Rashesh Chandrakant Gogri | MD & Executive Director | 27M | male |
| Harit Pragji Shah | Whole-Time Director | 27M | male |
| Uday Moreshwar Patil | Whole-Time Director | 27M | male |
| Harshit Manila Savla | Joint MD & Executive Director | 27M | male |
| Vishwa Harshit Savla | Managing Director of the Pinnacle Life Science Private Limited | — | male |
| Dhanaji L. Kakade | Vice President of Technical | — | male |
| Rushikesh Deole | Company Secretary & Compliance Officer | — | male |
| Adhish Prakash Patil | Chief Financial Officer & Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AARTIDRUGS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
